HomeALTME • EPA
add
TME Pharma NV
Previous close
€0.13
Day range
€0.13 - €0.14
Year range
€0.13 - €1.41
Market cap
6.76M EUR
Avg Volume
503.78K
P/E ratio
-
Dividend yield
-
Primary exchange
EPA
Market news
Financials
Income Statement
Revenue
Net income
| (EUR) | Dec 2023info | Y/Y change |
|---|---|---|
Revenue | — | — |
Operating expense | 1.42M | -33.74% |
Net income | -1.54M | 35.96% |
Net profit margin | — | — |
Earnings per share | — | — |
EBITDA | -1.41M | 33.94% |
Effective tax rate | -0.07% | — |
Balance Sheet
Total assets
Total liabilities
| (EUR) | Dec 2023info | Y/Y change |
|---|---|---|
Cash and short-term investments | 2.24M | -51.55% |
Total assets | 2.49M | -52.47% |
Total liabilities | 2.78M | -57.24% |
Total equity | -294.00K | — |
Shares outstanding | 17.28M | — |
Price to book | -6.73 | — |
Return on assets | -142.51% | — |
Return on capital | -407.11% | — |
Cash Flow
Net change in cash
| (EUR) | Dec 2023info | Y/Y change |
|---|---|---|
Net income | -1.54M | 35.96% |
Cash from operations | -1.12M | 64.34% |
Cash from investing | 0.00 | 100.00% |
Cash from financing | 738.00K | -48.54% |
Net change in cash | -381.50K | 77.28% |
Free cash flow | -756.56K | 35.57% |
About
TME Pharma, formerly NOXXON Pharma, is a biotechnology company founded in 1997 in Berlin, Germany which specialises on cancer treatment by targeting the tumor microenvironment. TME Pharma N.V. is listed on Euronext Growth, Paris and is a member of the German Association of Research-Based Pharmaceutical Companies, Verband forschender Arzneimittelhersteller.
TME Pharma develops drugs using technology yielding L-RNA molecules, which are of mirror-image configuration compared to naturally occurring D-RNA molecules. The company calls these agents Spiegelmers, from Spiegel, the German word for "mirror."
The L-RNA are resistant to the natural RNA nuclease enzymes. Wikipedia
Founded
1997
Website
Employees
13
